Cue Biopharma (CUE) Short Interest Ratio & Short Volume → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free CUE Stock Alerts $1.55 -0.10 (-6.06%) (As of 05/14/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Cue Biopharma Short Interest DataCurrent Short Volume4,960,000 sharesPrevious Short Volume4,780,000 sharesChange Vs. Previous Month+3.77%Dollar Volume Sold Short$9.42 millionShort Interest Ratio / Days to Cover17.2Last Record DateApril 30, 2024Outstanding Shares48,643,000 sharesPercentage of Shares Shorted10.20%Today's Trading Volume614,488 sharesAverage Trading Volume285,569 sharesToday's Volume Vs. Average215% Short Selling Cue Biopharma ? Sign up to receive the latest short interest report for Cue Biopharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatCUE Short Interest Over TimeCUE Days to Cover Over TimeCUE Percentage of Float Shorted Over Time Ad Porter & CompanyAmerica could fall from this eventAmerica’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash.Click here to see how you can protect yourself today. Cue Biopharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20244,960,000 shares $9.42 million +3.8%N/A17.2 $1.90 4/15/20244,780,000 shares $7.62 million +13.8%N/A18.7 $1.60 3/31/20244,200,000 shares $7.94 million +1.9%N/A15.8 $1.89 3/15/20244,120,000 shares $8.53 million +3.8%N/A14.7 $2.07 2/29/20243,970,000 shares $8.24 million +4.2%N/A12.7 $2.08 2/15/20243,810,000 shares $8.95 million +5.8%N/A10.8 $2.35 Get the Latest News and Ratings for CUE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter. 1/31/20243,600,000 shares $9.50 million -1.4%N/A10.6 $2.64 1/15/20243,650,000 shares $10.91 million +6.7%N/A10.1 $2.99 12/31/20233,420,000 shares $9.03 million +5.2%N/A9.4 $2.64 12/15/20233,250,000 shares $9.20 million +8.3%N/A9.5 $2.83 11/30/20233,000,000 shares $7.50 million -1.0%N/A10 $2.50 11/15/20233,030,000 shares $7.21 million -2.6%N/A11.8 $2.38 10/31/20233,110,000 shares $6.53 million +19.6%N/A10.2 $2.10 10/15/20232,600,000 shares $5.33 million +2.4%N/A8.2 $2.05 9/30/20232,540,000 shares $5.84 million +2.8%N/A6.7 $2.30 9/15/20232,470,000 shares $6.32 million +1.2%N/A5.2 $2.56 8/31/20232,440,000 shares $6.61 million -20.3%N/A5 $2.71 8/15/20233,060,000 shares $8.60 million -5.9%N/A6.2 $2.81 7/31/20233,250,000 shares $12.42 million +30.0%N/A7.1 $3.82 7/15/20232,500,000 shares $11.13 million +28.2%N/A5.5 $4.45 6/30/20231,950,000 shares $7.12 million +142.2%N/A5.4 $3.65 6/15/2023805,200 shares $3.12 million +10.1%N/A2.5 $3.87 5/31/2023731,600 shares $2.93 million +36.2%N/A3 $4.00 5/15/2023537,100 shares $2.39 million +1.0%N/A2.4 $4.45 4/30/2023531,900 shares $2.30 million -21.6%N/A2.8 $4.33 4/15/2023678,200 shares $2.36 million -10.5%N/A4.8 $3.48 3/31/2023757,900 shares $2.71 million +35.4%N/A5.5 $3.57 3/15/2023559,600 shares $1.75 million +21.8%N/A4.4 $3.12 2/28/2023459,500 shares $1.29 million +4.9%N/A4.3 $2.80 2/15/2023438,000 shares $1.47 million -12.7%N/A3.9 $3.35 1/31/2023501,900 shares $1.72 million -22.1%N/A3.9 $3.42 1/15/2023644,500 shares $2.24 million +8.8%N/A5 $3.48 12/30/2022592,200 shares $1.69 million -17.4%N/A4.4 $2.85 12/15/2022717,000 shares $2.03 million -5.7%N/A4.4 $2.83 11/30/2022759,900 shares $2.93 million -12.9%N/A4.8 $3.86 11/15/2022872,100 shares $3.30 million -29.7%N/A5.4 $3.78 10/31/20221,240,000 shares $3.30 million -10.8%N/A7.6 $2.66 10/15/20221,390,000 shares $3.57 million -6.1%N/A8.2 $2.57 9/30/20221,480,000 shares $3.30 million -12.4%N/A8.2 $2.23 9/15/20221,690,000 shares $5.53 million -12.9%N/A6 $3.27My system predicted the BA collapse – now it’s issuing an AI warning (Ad)Even after several plane crashes and equipment malfunctions... a congressional hearing... and the worst PR firestorm in recent memory... The FTC's commission chair Lina Khan still deems Boeing (BA), "too big to fail" Click to see why a similar situation is currently brewing in the AI market... CUE Short Interest - Frequently Asked Questions What is Cue Biopharma's current short interest? Short interest is the volume of Cue Biopharma shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 4,960,000 shares of CUE short. Learn More on Cue Biopharma's current short interest. What is a good short interest ratio for Cue Biopharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CUE shares currently have a short interest ratio of 17.0. Learn More on Cue Biopharma's short interest ratio. Which institutional investors are shorting Cue Biopharma? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Cue Biopharma: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Cue Biopharma's short interest increasing or decreasing? Cue Biopharma saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 4,960,000 shares, an increase of 3.8% from the previous total of 4,780,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Cue Biopharma's short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Cue Biopharma: Assertio Holdings, Inc. (12.08%), Allakos Inc. (6.31%), Citius Pharmaceuticals, Inc. (9.07%), Genelux Co. (11.62%), IO Biotech, Inc. (0.10%), PMV Pharmaceuticals, Inc. (6.93%), BeyondSpring Inc. (9.99%), Adagene Inc. (0.04%), Oramed Pharmaceuticals Inc. (0.80%), Relmada Therapeutics, Inc. (5.44%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Cue Biopharma stock? Short selling CUE is an investing strategy that aims to generate trading profit from Cue Biopharma as its price is falling. CUE shares are trading down $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Cue Biopharma? A short squeeze for Cue Biopharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CUE, which in turn drives the price of the stock up even further. How often is Cue Biopharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CUE, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: ASRT Short Squeeze ALLK Short Squeeze CTXR Short Squeeze GNLX Short Squeeze IOBT Short Squeeze PMVP Short Squeeze BYSI Short Squeeze ADAG Short Squeeze ORMP Short Squeeze RLMD Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CUE) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsCrypto Millionaire Says: “Buy This $11 AI Coin.”InvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperThe only AI company you should be looking atBehind the MarketsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing